CN102731532A - 一种头孢替坦二钠化合物、其制备方法及其药物组合物 - Google Patents
一种头孢替坦二钠化合物、其制备方法及其药物组合物 Download PDFInfo
- Publication number
- CN102731532A CN102731532A CN2012102354942A CN201210235494A CN102731532A CN 102731532 A CN102731532 A CN 102731532A CN 2012102354942 A CN2012102354942 A CN 2012102354942A CN 201210235494 A CN201210235494 A CN 201210235494A CN 102731532 A CN102731532 A CN 102731532A
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- pharmaceutical composition
- thf
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Cefotetan disodium compound Chemical class 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 229960004445 cefotetan disodium Drugs 0.000 title abstract description 7
- 239000013078 crystal Substances 0.000 claims abstract description 31
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 7
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 claims description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 63
- 239000000243 solution Substances 0.000 claims description 41
- 238000004108 freeze drying Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- 239000008215 water for injection Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 13
- 239000012046 mixed solvent Substances 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 9
- 238000005262 decarbonization Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 210000004907 gland Anatomy 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000009191 jumping Effects 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 7
- 229960005495 cefotetan Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229910017488 Cu K Inorganic materials 0.000 claims description 5
- 229910017541 Cu-K Inorganic materials 0.000 claims description 5
- 230000005260 alpha ray Effects 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 7
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 abstract description 4
- 229910002483 Cu Ka Inorganic materials 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 239000003814 drug Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 238000012856 packing Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- 238000005374 membrane filtration Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010013786 Dry skin Diseases 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229920005549 butyl rubber Polymers 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000005496 eutectics Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010004142 Bartholinitis Diseases 0.000 description 1
- 206010061695 Biliary tract infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229940105726 cefotan Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
取样时间(10小时) | 与0小时相比,增重% |
样品1 | 3.63 |
样品2 | 3.64 |
对照1 | 8.12 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210235494.2A CN102731532B (zh) | 2012-07-09 | 2012-07-09 | 一种头孢替坦二钠化合物、其制备方法及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210235494.2A CN102731532B (zh) | 2012-07-09 | 2012-07-09 | 一种头孢替坦二钠化合物、其制备方法及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102731532A true CN102731532A (zh) | 2012-10-17 |
CN102731532B CN102731532B (zh) | 2014-02-26 |
Family
ID=46987906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210235494.2A Active CN102731532B (zh) | 2012-07-09 | 2012-07-09 | 一种头孢替坦二钠化合物、其制备方法及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102731532B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103073563A (zh) * | 2013-01-23 | 2013-05-01 | 海南通用三洋药业有限公司 | 一种头孢替坦二钠的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007122628A1 (en) * | 2006-04-21 | 2007-11-01 | Lupin Limited | Improved process for preparation of highly pure cefotetan disodium |
CN102247375A (zh) * | 2011-05-20 | 2011-11-23 | 海南合瑞制药股份有限公司 | 一种注射用头孢替坦二钠及其制备方法 |
-
2012
- 2012-07-09 CN CN201210235494.2A patent/CN102731532B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007122628A1 (en) * | 2006-04-21 | 2007-11-01 | Lupin Limited | Improved process for preparation of highly pure cefotetan disodium |
CN102247375A (zh) * | 2011-05-20 | 2011-11-23 | 海南合瑞制药股份有限公司 | 一种注射用头孢替坦二钠及其制备方法 |
Non-Patent Citations (2)
Title |
---|
《抗感染药学》 20081231 刘旻虹 头孢菌素类抗生素-头孢替坦的研究进展 第209-214页 1-9 第5卷, 第4期 * |
刘旻虹: "头孢菌素类抗生素—头孢替坦的研究进展", 《抗感染药学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103073563A (zh) * | 2013-01-23 | 2013-05-01 | 海南通用三洋药业有限公司 | 一种头孢替坦二钠的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102731532B (zh) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101606910B (zh) | 一种头孢唑肟钠药物粉针剂及其制备方法、及原料药头孢唑肟钠的合成方法 | |
CN101623285A (zh) | 一种头孢美唑钠药物及其制备方法 | |
CN103524532B (zh) | 一种头孢唑肟钠化合物晶型、制备方法及其药物制剂 | |
CN102525963A (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN103601739A (zh) | 一种头孢西丁钠化合物及其制备方法 | |
CN102247375B (zh) | 一种注射用头孢替坦二钠及其制备方法 | |
CN103446075A (zh) | 一种头孢克洛胶囊及其制备方法 | |
CN102731532A (zh) | 一种头孢替坦二钠化合物、其制备方法及其药物组合物 | |
CN102276630A (zh) | 一种头孢米诺钠结晶化合物及其组合物粉针 | |
CN105496984B (zh) | 一种质量稳定的头孢克肟胶囊及其制备方法 | |
CN106432274A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
CN106432278A (zh) | 一种治疗外科手术感染的药物头孢曲松钠晶体化合物 | |
CN106432279A (zh) | 一种制备治疗外科手术感染的药物头孢曲松钠晶体化合物的方法 | |
CN112957332A (zh) | 注射用磷酸特地唑胺及其质量标准 | |
CN105622635A (zh) | 一种减少过敏反应的头孢唑肟钠新晶型及其制剂 | |
CN105640895A (zh) | 一种头孢羟氨苄颗粒制剂及其制备方法 | |
CN106310286B (zh) | 一种甲苯磺酸妥舒沙星组合物 | |
CN101829119B (zh) | 头孢地秦钠组合物及其粉针 | |
CN104072400A (zh) | 一种奥拉西坦化合物及其药物组合物 | |
CN106366099B (zh) | 一种抗感染药物头孢曲松钠晶体化合物及其制备方法 | |
CN105125558A (zh) | 一种抗菌药物盐酸头孢替安组合物 | |
CN103450086A (zh) | 一种奥扎格雷化合物、制备方法及其药物组合物 | |
CN103304604A (zh) | 一种克林霉素磷酸酯化合物,其制备方法及其药物组合物 | |
CN108653224A (zh) | 一种阿莫西林片剂及其制备方法 | |
CN103159784A (zh) | 一种头孢呋辛赖氨酸及其制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Cefotetan disodium compound as well as preparation method and medicinal composition thereof Effective date of registration: 20170518 Granted publication date: 20140226 Pledgee: Agricultural Bank of China, Limited by Share Ltd, Haikou branch of science and technology Pledgor: Hainan Herui Pharmaceutical Co., Ltd. Registration number: 2017460000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180911 Granted publication date: 20140226 Pledgee: Agricultural Bank of China, Limited by Share Ltd, Haikou branch of science and technology Pledgor: Hainan Herui Pharmaceutical Co., Ltd. Registration number: 2017460000007 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201230 Address after: No. 584, xinqiong village, Dapu Town, Yongchun County, Quanzhou City, Fujian Province, 362600 Patentee after: Ye Shenghai Address before: 570311 Pharmaceutical Valley Industrial Park, Haikou National High-tech Zone, Haikou City, Hainan Province, Phase II Patentee before: HAINAN HERUI PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210120 Address after: Liu'an Development Zone, Yongchun County, Quanzhou City, Fujian Province (east side of Taoxi bridge) Patentee after: Yongchun County Product Quality Inspection Institute Fujian fragrance product quality inspection center, national incense burning product quality supervision and Inspection Center (Fujian) Address before: No. 584, xinqiong village, Dapu Town, Yongchun County, Quanzhou City, Fujian Province, 362600 Patentee before: Ye Shenghai |